DGX — Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: New York Stock Exchange
- Employees: 55,000
- Website: https://www.questdiagnostics.com
Latest SEC filings for DGX
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 10-Q — 2026-10-23
- 11-K — 2026-06-18
Latest DGX news
- — Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term (Zacks Investment Research)
- — Quest Diagnostics outlines $12.065B-$12.105B 2026 revenue outlook while projecting consumer health growth to exceed 30% (seekingalpha_market)
- — DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market (Zacks Investment Research)
- — Quest Diagnostics boosts 2026 revenue, EPS guidance (seekingalpha_market)
- — Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates (Zacks Investment Research)
- — Quest Diagnostics Non-GAAP EPS of $3.00 beats by $0.13, revenue of $3.1B beats by $50M (seekingalpha_market)
- — Quest Diagnostics Q3 2026 Earnings Preview (seekingalpha_market)
- — Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings (zacks.com)
- — Here's Why Quest Diagnostics (DGX) is a Strong Value Stock (zacks.com)
- — Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus (Zacks Investment Research)
Educational tool only — not investment advice.